Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10456134" target="_blank" >RIV/00064165:_____/22:10456134 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10456134
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=eEcG.QFRcw" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=eEcG.QFRcw</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2022.280660" target="_blank" >10.3324/haematol.2022.280660</a>
Alternative languages
Result language
angličtina
Original language name
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Original language description
Gain/amplification of 1q21, referred to as 1q21+ in this letter, is one of the most common chromosomal abnormalities in multiple myeloma (MM), being detected in approximately 40% of patients at diagnosis. The number of MM cells with 1q21+ and the number of copies of 1q21+ increases as the disease progresses. Furthermore, its negative impact on prognosis suggests that 1q21+ is involved in the pathophysiology of disease progression and resistance to MM treatment. The 1q21+ abnormality is defined as gain of 1q21 (gain[1q21], 3 copies) and amplification of 1q21 (amp[1q21], >=4 copies). Co-existence of certain high-risk chromosomal abnormalities is common and further worsens the prognosis for patients with 1q21+. In the phase III studies ICARIA-MM and IKEMA, the addition of the anti-CD38 monoclonal antibody isatuximab (Isa) to the backbone of pomalidomide-dexamethasone (Pd) or carfilzomib-dexamethasone (Kd), respectively, improved progression-free survival (PFS) among patients with relapsed/refractory MM, and subgroup analyses suggested benefit among patients with 1q21+. The current analyses examine four subgroups of patients from ICARIA-MM and IKEMA: 1q21+ (>=3 copies with or without high-risk chromosomal abnormalities), isolated 1q21+ (>=3 copies without high-risk chromosomal abnormalities), gain(1q21) (3 copies with or without high-risk chromosomal abnormalities), and amp(1q21) (>=4 copies with or without high-risk chromosomal abnormalities). The analyses show a clear benefit of Isa-based combinations in 1q21+ disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Haematologica
ISSN
0390-6078
e-ISSN
1592-8721
Volume of the periodical
107
Issue of the periodical within the volume
10
Country of publishing house
IT - ITALY
Number of pages
7
Pages from-to
2485-2491
UT code for WoS article
000870533100022
EID of the result in the Scopus database
2-s2.0-85139536296